Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses

  Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into
  Agreement to Combine Businesses

 Transaction Will Add Breakthrough Biologics Platform and Pipeline to Further
       Accelerate Growth Opportunities in Wright’s Extremities Business

    Upfront Purchase Price Payment of $190 Million in Cash and Stock Plus
                  Contingent Payments of up to $190 Million

       Wright to Host Conference Call Today at 10:00 a.m. Central Time

Business Wire

ARLINGTON, Tenn. & FRANKLIN, Tenn. -- November 19, 2012

Wright Medical Group, Inc. (NASDAQ: WMGI) and BioMimetic Therapeutics, Inc.
(NASDAQ: BMTI) announced today that they have entered into a definitive
agreement for a business combination of Wright and BioMimetic, both publicly
traded, Tennessee-based companies. Wright is an orthopedics company with a
market-leading lower extremities franchise. BioMimetic is focused on
developing regenerative medicine products to promote the healing of
musculoskeletal injuries and diseases with a novel protein therapeutic
product, Augment^® Bone Graft, under late stage FDA review as a replacement
for autologous bone graft in foot and ankle fusions. The transaction will
combine BioMimetic’s breakthrough biologics platform and pipeline with
Wright’s established sales force and product portfolio, to further accelerate
growth opportunities in Wright’s Extremities business.

Under the terms of the agreement, the transaction has a total potential value
for BioMimetic shareholders of approximately $380 million, or $12.97 per
share, based on Wright’s closing stock price on Friday, November 16, 2012.
Each share of BioMimetic common stock will be converted into the right to
receive an upfront payment of $1.50 in cash and 0.2482 shares of Wright common
stock. The upfront payment values BioMimetic at approximately $190 million, or
$6.47 per share, based on Wright’s closing stock price on November 16, 2012.
Each BioMimetic share will also receive one tradable Contingent Value Right
(CVR), which entitles its holder to receive additional cash payments of up to
$6.50 per share, which are payable upon receipt of FDA approval of Augment^®
Bone Graft and upon achieving certain revenue milestones.

Any contingent milestone payments will be paid in cash. The CVR payments to
BioMimetic shareholders are structured as follows:

  *$3.50 per share upon FDA approval of Augment^® Bone Graft;
  *$1.50 per share upon the achievement of $40 million in trailing twelve
    month sales for all products contributed by BioMimetic;
  *$1.50 per share upon the achievement of $70 million in trailing twelve
    month sales for all products contributed by BioMimetic.

The latter two sales milestone payments cannot be made sooner than 24 and 36
months post-closing of the transaction, respectively.

The transaction is expected to close in the first quarter of 2013 and is
subject to customary closing conditions, including BioMimetic shareholder
approval. The transaction received the unanimous approval of the board of
directors of both Wright and BioMimetic. In addition, several key shareholders
of BioMimetic have evidenced their support of the transaction by entering into
agreements to vote in favor of the transaction.

Robert Palmisano, President and Chief Executive Officer of Wright, commented,
“We believe this transaction will significantly accelerate the continued
transformation of our business as well as our strategy of building a
world-class biologics platform and growing our foot and ankle business at well
above market growth rates. BioMimetic’s products complement our existing
biologics product portfolio, and, if approved by the FDA as we expect,
Augment^® Bone Graft will provide us with a unique solution for the U.S.
hindfoot and ankle fusion market that leverages the distribution capabilities
of Wright’s dedicated foot and ankle sales organization and our physician
training capabilities.”

Dr. Samuel Lynch, President and Chief Executive Officer of BioMimetic
Therapeutics, added, “BioMimetic is delighted to partner with a company that
shares our commitment to building a world-class biologics platform. We believe
that Augment^® Bone Graft will become an important new therapeutics option to
improve patient outcomes in hindfoot and ankle fusion procedures, and that
Wright Medical with its leadership position in the foot and ankle market is
the ideal partner to accelerate the rapid adoption of our products around the
world.”

BioMimetic’s Augment^® product line is based on recombinant human
platelet-derived growth factor (rhPDGF-BB), a synthetic copy of one of the
body’s principal healing agents. In May 2011, the FDA’s Orthopaedic and
Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted
favorably on Augment^® Bone Graft’s safety, efficacy and benefit to risk
profile for its use as an alternative to autograft in hindfoot and ankle
fusions. In January 2012, BioMimetic announced receipt of a post-panel
non-approvable letter requesting additional information in a PMA amendment. In
June 2012, BioMimetic submitted a responsive PMA amendment, and the product is
currently pending a final FDA regulatory decision. If approved, Augment^® Bone
Graft will be the first clinically proven protein therapeutic to come to the
orthopedics market in a decade, offering the potential to reinforce surgical
bone repair in hindfoot and ankle fusion procedures effectively, which
translates into an estimated market opportunity believed to be approximately
$300 million annually in the U.S. Augment^® Bone Graft is currently available
for sale as an alternative to autograft in Canada for foot and ankle fusion
indications and in Australia and New Zealand for hindfoot and ankle fusion
indications.

Although Wright cannot finalize the purchase price allocation and fair value
assessment of the contingent consideration until the closing, and thus cannot
yet assess the exact impact on its future GAAP earnings, Wright anticipates
that the transaction will be dilutive to adjusted EBITDA until the second
full-year post-FDA approval of Augment^® Bone Graft and accretive thereafter.
Wright will provide additional information on the financial impact of this
transaction after the closing.

In connection with this transaction, J.P. Morgan Securities LLC and Wilson
Sonsini Goodrich & Rosati, a Professional Corporation advised Wright Medical,
and Goldman, Sachs & Co. and Ropes & Gray LLP advised BioMimetic Therapeutics.

Conference Call and Webcast

Wright Medical will host a conference call today, November 19, 2012, beginning
at 10:00 a.m. Central Time (11:00 a.m. Eastern Time) to discuss the BioMimetic
transaction, followed by a question and answer session.

The conference call will be available to interested parties through a live
audio webcast at www.wmt.com, where it will be archived and accessible for
approximately 12 months. The live dial-in number for the call is 800-591-6930
(U.S.) or 617-614-4908 (International). The participant passcode is “Wright.”

If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial 888-286-8010 (U.S.) or 617-801-6888
(International) and enter passcode 47252247. The audio replay will be
available beginning at 12:00 p.m. Central Time on Monday, November 19, 2012
until Monday, November 27, 2012.

About Wright Medical

Wright Medical Group, Inc. (NASDAQ: WMGI) is a global orthopaedic medical
device company and a leading provider of surgical solutions for the foot and
ankle market. Wright Medical specializes in the design, manufacture and
marketing of devices and biologic products for extremity, hip and knee repair
and reconstruction. Wright Medical has been in business for more than 60 years
and markets its products in over 60 countries worldwide. For more information
about Wright Medical, visit the Wright Medical’s website at www.wmt.com.

About BioMimetic Therapeutics, Inc.

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) is a biotechnology company
specializing in the development and commercialization of clinically proven
products to promote the healing of musculoskeletal injuries and diseases,
including therapies for orthopedics, sports medicine and spine applications.
All Augment^® branded products are based upon recombinant human
platelet-derived growth factor (rhPDGF-BB), which is an engineered form of
PDGF, one of the body’s principal agents to stimulate and direct healing and
regeneration. Through the commercialization of this patented technology,
BioMimetic seeks to become the leading company in the field of regenerative
medicine by providing new treatment options for the repair of bone, cartilage,
tendons and ligaments.

BioMimetic has received regulatory approvals to market Augment^® Bone Graft in
Canada, Australia and New Zealand for use in hindfoot and ankle fusion
indications. Augment^® is pending regulatory decisions in the U.S. and
European Union for similar indications. BioMimetic also markets a bone graft
substitute line of products for orthopedic indications called Augmatrix^™
Biocomposite Bone Graft. For more information about BioMimetic, visit
BioMimetic’s website at www.biomimetics.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” as defined under
U.S. federal securities laws. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and express
management’s current view of future performance, results, and trends. Forward
looking statements may be identified by their use of terms such as anticipate,
believe, could, estimate, expect, intend, may, plan, predict, project, will,
and other similar terms. Forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results to materially differ
from those described in the forward-looking statements. In addition to those
described below, forward looking statements contained in this press release
include, without limitation, statements concerning the possibility of FDA
approval of Augment Bone Graft, statements regarding market acceptance of, and
expected annual market demand for Augment Bone Graft, statements regarding the
expected impact of the transaction with BioMimetic on Wright’s adjusted EBITDA
and other financial results, and statements about the timing and expected
benefits of the transaction. The reader should not place undue reliance on
forward-looking statements. Such statements are made as of the date of this
press release, and we undertake no obligation to update such statements after
this date. In addition to those described above, risks and uncertainties that
could cause our actual results to materially differ from those described in
forward-looking statements are discussed in our filings with the Securities
and Exchange Commission (including those described in Item 1A of our Annual
Report on Form 10-K for the year ended December 31, 2011 and our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012, in each case
under the heading “Risk Factors” and elsewhere in such filings). By way of
example and without implied limitation, such risks and uncertainties include:
the failure of BioMimetic stockholders to adopt the merger agreement or the
failure of either Wright or BioMimetic to meet any of the other conditions to
the closing of the transaction, the failure to realize the anticipated
benefits from the transaction or delay in realization thereof, future actions
of the United States Attorney’s office, the FDA, the Department of Health and
Human Services or other U.S. or foreign government authorities that could
delay, limit or suspend our development, manufacturing, commercialization and
sale of products, or result in seizures, injunctions, monetary sanctions or
criminal or civil liabilities; any actual or alleged breach of the Corporate
Integrity Agreement to which we are subject through September 2015 which could
expose us to significant liability including exclusion from Medicare, Medicaid
and other federal healthcare programs, potential criminal prosecution, and
civil and criminal fines or penalties; adverse outcomes in existing product
liability litigation; new product liability claims; inadequate insurance
coverage; the possibility of private securities litigation or shareholder
derivative suits; demand for and market acceptance of our new and existing
products; potentially burdensome tax measures; lack of suitable business
development opportunities; product quality or patient safety issues;
challenges to our intellectual property rights; geographic and product mix
impact on our sales; our inability to retain key sales representatives,
independent distributors and other personnel or to attract new talent;
inventory reductions or fluctuations in buying patterns by wholesalers or
distributors; inability to realize the anticipated benefits of restructuring
initiatives; negative impact of the commercial and credit environment on us,
our customers and our suppliers; and the potentially negative effect of our
ongoing compliance enhancements on our relationships with customers, and on
our ability to deliver timely and effective medical education, clinical
studies, and new products.

ADDITIONAL INFORMATION ABOUT THIS TRANSACTION

This press release may be deemed to be solicitation material regarding the
proposed business combination of Wright and BioMimetic. In connection with the
proposed transaction, Wright intends to file with the SEC a registration
statement on Form S-4, which will include a proxy statement/prospectus and
other relevant materials in connection with the proposed transaction, and each
of Wright and BioMimetic intend to file with the SEC other documents regarding
the proposed transaction. The proxy statement/prospectus and this press
release are not offers to sell Wright securities and are not soliciting an
offer to buy Wright securities in any state where the offer and sale is not
permitted. The final proxy statement/prospectus will be mailed to the
stockholders of BioMimetic. INVESTORS AND SECURITY HOLDERS OF BIOMIMETIC ARE
URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR
SUPPLEMENTS THERETO) AND THE OTHER RELEVANT MATERIAL CAREFULLY IN THEIR
ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT WRIGHT AND BIOMIMETIC AND THE PROPOSED TRANSACTION.

The proxy statement/prospectus and other relevant materials (when they become
available), and any and all documents filed with the SEC, may be obtained free
of charge at the SEC’s web site at www.sec.gov. In addition, investors and
security holders may obtain free copies of the documents filed with the SEC by
Wright by directing a written request to Wright Medical Group, Inc, 5677
Airline Road, Arlington, TN 38002, Attention: Investor Relations, and by
BioMimetic by directing a written request to BioMimetic Therapeutics, Inc.,
389 Nichol Mill Lane, Franklin, TN 37067, Attention: Investor Relations.

BioMimetic and its respective executive officers and directors and other
persons, including Wright and its respective executive officers and directors,
may be deemed to be participants in the solicitation of proxies from its
stockholders in connection with the proposed transaction. Information about
the executive officers and directors of BioMimetic and their ownership of
BioMimetic common stock is set forth in its annual report on Form 10-K for the
year ended December 31, 2011, filed with the SEC on March 13, 2012 and the
proxy statement for BioMimetic’s 2012 annual meeting of stockholders, filed
with the SEC on April 27, 2012. Information about the executive officers and
directors of Wright Medical Group is set forth in its annual report on Form
10-K for the year ended December 31, 2011, filed with the SEC on February 24,
2012 and the proxy statement for Wright Medical Group’s 2012 annual meeting of
stockholders, filed with the SEC on March 27, 2012. Certain directors and
executive officers of BioMimetic and other persons may have direct or indirect
interests in the merger due to securities holdings, pre-existing or future
indemnification arrangements and rights to severance payments if their
employment is terminated prior to or following the transaction. If and to the
extent that any of the BioMimetic participants will receive any additional
benefits in connection with the transaction, the details of those benefits
will be described in the proxy statement/prospectus relating to the
transaction. Investors and security holders may obtain additional information
regarding the direct and indirect interests of BioMimetic and its executive
officers and directors in the transaction by reading the proxy
statement/prospectus regarding the transaction when it becomes available.

Contact:

Wright Medical Group, Inc.
Julie D. Tracy, 901-290-5817 (office)
Sr. Vice President, Chief Communications Officer
julie.tracy@wmt.com
or
BioMimetic Therapeutics, Inc.
Kearstin Patterson, 615-236-4419 (office)
mobile: 615-517-6112
Sr. Director of Corporate Communications
kpatterson@biomimetics.com